The Role of Immunological Synapse in Predicting the Efficacy of Chimeric Antigen Receptor (CAR) Immunotherapy

Abstract Chimeric Antigen Receptor (CAR) immunotherapy utilizes genetically-engineered immune cells that express a unique cell surface receptor that combines tumor antigen specificity with immune cell activation. In recent clinical trials, the adoptive transfer of CAR-modified immune cells (including CAR-T and CAR-NK cells) into patients has been remarkably successful in treating multiple refractory blood cancers. To improve safety and efficacy, and expand potential applicability to other cancer types, CARs with different target specificities and sequence modifications are being developed and tested by many laboratories. Despite the overall progress in CAR immunotherapy, conventional tools to design and evaluate the efficacy and safety of CAR immunotherapies can be inaccurate, time-consuming, costly, and labor-intensive. Furthermore, existing tools cannot always determine how responsive individual patients will be to a particular CAR immunotherapy. Recent work in our laboratory suggests that the quality of the immunological synapse (IS) can accurately predict CAR-modified cell efficacy (and toxicity) that can correlate with clinical outcomes. Here we review current efforts to develop a Synapse Predicts Efficacy (SPE) system for easy, rapid and cost-effective evaluation of CAR-modified immune cell immunotherapy. Ultimately, we hypothesize the conceptual basis and clinical application of SPE will serve as an important parameter in evaluating CAR immunotherapy and significantly advance precision cancer immunotherapy. Video abstract Graphical abstract Graphic abstract for manuscript CCAS-D-20-00136 by Liu, D., et al., ‘The Role of Immunological Synapse in Predicting the Efficacy of Chimeric Antigen Receptor (CAR) Immunotherapy”. The various branches of evaluating cancer immunotherapy metaphorically represented as a Rubik’s cube. The development of a novel approach to predict the effectiveness of Chimeric Antigen Receptor (CAR)-modified cells by quantifying the quality of CAR IS will introduce a new parameter to the rapidly expanding field of cancer immunotherapy. Currently, no single parameter can predict the clinical outcome or efficacy of a specific type of CAR-modified cell. IS quality will serve as a quantifiable measure to evaluate CAR products and can be used in conjunction with other conventional parameters to form a composite clinical predictor. Much like a Rubik’s cube has countless configurations, several methods and combinations of clinical metrics have arisen for evaluating the ability of a given immunotherapeutic strategy to treat cancer. The quality of IS depicting cancer immunotherapy is metaphorically expressed as a Rubik’s cube. Each face/color represents one aspect of cancer therapy. Each grid in one face indicates one factor within that aspect of cancer therapy. For example, the green color represents the tumor microenvironment, and one out of the nine grids in the green color indicates suppressor cells (suppressors in green). Changes in one factor may completely alter the entire strategy of cancer therapy. However, the quality of IS (illuminated center red grid) makes the effectiveness of CAR immunotherapy predictable.

[1]  Yang Zhang,et al.  Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward , 2018, Journal of Hematology & Oncology.

[2]  M. Kriegsmann,et al.  NKT cells — New players in CAR cell immunotherapy? , 2018, European journal of haematology.

[3]  Michael Loran Dustin,et al.  Functional anatomy of T cell activation and synapse formation. , 2010, Annual review of immunology.

[4]  B. Tannous,et al.  A water-soluble coelenterazine for sensitive in vivo imaging of coelenterate luciferases. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[5]  Y. Tokura,et al.  Interleukin‐10 expressed at early tumour sites induces subsequent generation of CD4+ T‐regulatory cells and systemic collapse of antitumour immunity , 2001, Immunology.

[6]  M. Sadelain,et al.  CAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade , 2018, Nature Medicine.

[7]  Pamela A Shaw,et al.  Chimeric antigen receptor T cells for sustained remissions in leukemia. , 2014, The New England journal of medicine.

[8]  Yi-Hsin Hsu,et al.  Immunological Synapse Predicts Effectiveness of Chimeric Antigen Receptor Cells , 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

[9]  G. Rabinovich,et al.  Immunosuppressive strategies that are mediated by tumor cells. , 2007, Annual review of immunology.

[10]  T. Luetkens,et al.  Chimeric Antigen Receptor (CAR) therapy for multiple myeloma , 2016, British journal of haematology.

[11]  Bernd Hauck,et al.  Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. , 2013, The New England journal of medicine.

[12]  S. Grupp,et al.  Current concepts in the diagnosis and management of cytokine release syndrome. , 2014, Blood.

[13]  M. Sadelain,et al.  Tumor-Targeted Human T Cells Expressing CD28-Based Chimeric Antigen Receptors Circumvent CTLA-4 Inhibition , 2015, PloS one.

[14]  Jedd D. Wolchok,et al.  Cancer immunotherapy using checkpoint blockade , 2018, Science.

[15]  J. Kochenderfer,et al.  Toxicities of chimeric antigen receptor T cells: recognition and management. , 2016, Blood.

[16]  Tyler J. Reich,et al.  Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells , 2018, Nature.

[17]  A. Bagg,et al.  Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma. , 2015, The New England journal of medicine.

[18]  J. Maher,et al.  Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors , 2018, Front. Immunol..

[19]  M. Brown,et al.  GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 Blockade. , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

[20]  D. Kaufman,et al.  Off-the-shelf cell therapy with induced pluripotent stem cell-derived natural killer cells , 2018, Seminars in Immunopathology.

[21]  S. Furlan,et al.  Human CD19-Targeted Mouse T Cells Induce B Cell Aplasia and Toxicity in Human CD19 Transgenic Mice. , 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

[22]  W. Pickl,et al.  The making and function of CAR cells , 2019, Immunology letters.

[23]  Jennifer Abbasí.  Amid FDA Approval Filings, Another CAR-T Therapy Patient Death. , 2017, JAMA.

[24]  G. Dotti,et al.  Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. , 2010, Blood.

[25]  S. Rosenberg,et al.  Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Sadik H. Kassim,et al.  Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. , 2013, Blood.

[27]  A. Bagg,et al.  Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. , 2011, The New England journal of medicine.

[28]  Juanjuan Zhao,et al.  Universal CARs, universal T cells, and universal CAR T cells , 2018, Journal of Hematology & Oncology.

[29]  Axel Schambach,et al.  Engineering CAR-T Cells for Improved Function Against Solid Tumors , 2018, Front. Immunol..

[30]  P. Sharma,et al.  Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential , 2015, Cell.

[31]  R. Hawkins,et al.  Overcoming the toxicity hurdles of genetically targeted T cells , 2014, Cancer Immunology, Immunotherapy.

[32]  C. Rooney,et al.  Adenovector-induced expression of human-CD40-ligand (hCD40L) by multiple myeloma cells. A model for immunotherapy. , 2001, Experimental hematology.

[33]  E. Puré,et al.  Augmentation of CAR T-cell Trafficking and Antitumor Efficacy by Blocking Protein Kinase A Localization , 2016, Cancer Immunology Research.

[34]  Yi Zhang,et al.  Chimeric Antigen Receptor T Cell Based Immunotherapy for Cancer. , 2018, Current stem cell research & therapy.

[35]  Seth M Steinberg,et al.  T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial , 2015, The Lancet.

[36]  Sanjiv S Gambhir,et al.  Multimodality imaging of lymphocytic migration using lentiviral-based transduction of a tri-fusion reporter gene. , 2004, Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging.

[37]  Haifeng Song,et al.  A safe and potent anti-CD19 CAR T cell therapy , 2019, Nature Medicine.

[38]  Haidong Dong,et al.  Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.

[39]  B. Suarez-Alvarez,et al.  Acute myeloid leukemia and NK cells: two warriors confront each other , 2018, Oncoimmunology.

[40]  Hao Liu,et al.  Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes. , 2017, The Journal of clinical investigation.

[41]  Sadik H. Kassim,et al.  Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  M. Sadelain,et al.  Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. , 2012, Blood.

[43]  M. Del Vecchio,et al.  Immunotherapy of Metastatic Melanoma Using Genetically Engineered GD2-Specific T cells , 2009, Clinical Cancer Research.

[44]  H. Abken,et al.  CAR T Cells Releasing IL-18 Convert to T-Bethigh FoxO1low Effectors that Exhibit Augmented Activity against Advanced Solid Tumors. , 2017, Cell reports.

[45]  Abdolreza Esmaeilzadeh,et al.  Solid Tumors Challenges and New Insights of CAR T Cell Engineering , 2019, Stem Cell Reviews and Reports.

[46]  C. June,et al.  Driving gene-engineered T cell immunotherapy of cancer , 2016, Cell Research.

[47]  G. Freeman,et al.  PD-1 and its ligands in tolerance and immunity. , 2008, Annual review of immunology.

[48]  M. Sadelain,et al.  Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[49]  S. Gambhir,et al.  Optical imaging of Renilla luciferase reporter gene expression in living mice , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[50]  João Nuno Moreira,et al.  Current challenges and emerging opportunities of CAR-T cell therapies. , 2019, Journal of controlled release : official journal of the Controlled Release Society.

[51]  Hans Bitter,et al.  Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia , 2018, Nature Medicine.

[52]  S. Grupp,et al.  Nature of Tumor Control by Permanently and Transiently Modified GD2 Chimeric Antigen Receptor T Cells in Xenograft Models of Neuroblastoma , 2014, Cancer Immunology Research.

[53]  C. Cruz,et al.  Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. , 2013, Blood.

[54]  Peilin Zheng,et al.  Imaging of Cell–Cell Communication in a Vertical Orientation Reveals High-Resolution Structure of Immunological Synapse and Novel PD-1 Dynamics , 2015, The Journal of Immunology.

[55]  J. Orange,et al.  Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity , 2018, Leukemia.

[56]  Pierre Validire,et al.  Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors. , 2012, The Journal of clinical investigation.

[57]  S. Riddell,et al.  Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy , 2018, The Journal of Immunology.

[58]  Rajat Varma,et al.  T cell receptor-proximal signals are sustained in peripheral microclusters and terminated in the central supramolecular activation cluster. , 2006, Immunity.

[59]  E. Boyer,et al.  Chimeric antigen receptor T-cell toxicity , 2019, Current opinion in pediatrics.

[60]  P. Hwu,et al.  Chimeric antigen receptor T-cell therapy — assessment and management of toxicities , 2018, Nature Reviews Clinical Oncology.

[61]  Vinay Prasad,et al.  Immunotherapy: Tisagenlecleucel — the first approved CAR-T-cell therapy: implications for payers and policy makers , 2018, Nature Reviews Clinical Oncology.

[62]  Zhiqiang Wu,et al.  PD-1 silencing impairs the anti-tumor function of chimeric antigen receptor modified T cells by inhibiting proliferation activity , 2019, Journal of Immunotherapy for Cancer.

[63]  K. Kinzler,et al.  Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome , 2018, Nature.

[64]  R. Levy,et al.  Axicabtagene Ciloleucel CAR T‐Cell Therapy in Refractory Large B‐Cell Lymphoma , 2017, The New England journal of medicine.

[65]  S. Albelda,et al.  CAR T Cell Therapy for Solid Tumors. , 2017, Annual review of medicine.

[66]  C. June,et al.  Predicting Dangerous Rides in CAR T Cells: Bridging the Gap between Mice and Humans. , 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

[67]  Anping Li,et al.  Chimeric antigen receptor T cells: a novel therapy for solid tumors , 2017, Journal of Hematology & Oncology.

[68]  R. Brentjens,et al.  Development of CAR T cells designed to improve antitumor efficacy and safety. , 2017, Pharmacology & therapeutics.

[69]  P. Gimotty,et al.  Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy , 2008, Nature Medicine.

[70]  H. Heslop,et al.  Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety , 2010, Leukemia.

[71]  M. Maus,et al.  Making CAR T Cells a Solid Option for Solid Tumors , 2018, Front. Immunol..

[72]  E. Moon,et al.  CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment , 2019, Front. Immunol..

[73]  Thor A Wagner.  Quarter Century of Anti-HIV CAR T Cells , 2018, Current HIV/AIDS Reports.

[74]  A. Allegra,et al.  Adoptive immunotherapy for hematological malignancies: Current status and new insights in chimeric antigen receptor T cells. , 2016, Blood cells, molecules & diseases.

[75]  T. Fry,et al.  Mechanisms of resistance to CAR T cell therapy , 2019, Nature Reviews Clinical Oncology.

[76]  G. Zhu,et al.  Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.

[77]  V. Seshan,et al.  Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo , 2018, Nature Biotechnology.

[78]  R. Brentjens,et al.  Armored CAR T-cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumour efficacy. , 2016, Biochemical Society transactions.

[79]  M. Dhodapkar,et al.  Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance , 2018, Journal of Immunotherapy for Cancer.

[80]  Hans Anton Schlößer,et al.  Cytokine release syndrome , 2018, Journal of Immunotherapy for Cancer.

[81]  P. Duchateau,et al.  ‘Off-the-shelf’ allogeneic CAR T cells: development and challenges , 2020, Nature Reviews Drug Discovery.

[82]  Z. Berneman,et al.  Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen , 2019, Front. Immunol..

[83]  S. Rosenberg,et al.  Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[84]  P. Darcy,et al.  Adoptive cell therapy (ACT) utilizing gene-modified T cells expressing chimeric antigen receptors (CAR) has emerged as a promising regimen for the treatment of a broad range of cancers including chronic lymphoid leukaemia and neuroblastoma , 2013 .

[85]  Daniel Li,et al.  CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. , 2016, The Journal of clinical investigation.

[86]  Rajat Varma,et al.  Actin and agonist MHC–peptide complex–dependent T cell receptor microclusters as scaffolds for signaling , 2005, The Journal of experimental medicine.

[87]  David L. Porter,et al.  T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia , 2011, Science Translational Medicine.

[88]  K. Mills,et al.  Suppression of Antitumor Immunity by IL-10 and TGF-β-Producing T Cells Infiltrating the Growing Tumor: Influence of Tumor Environment on the Induction of CD4+ and CD8+ Regulatory T Cells1 , 2006, The Journal of Immunology.

[89]  Carl H. June,et al.  Expanding the Therapeutic Window for CAR T Cell Therapy in Solid Tumors: The Knowns and Unknowns of CAR T Cell Biology , 2018, Front. Immunol..

[90]  Michel Sadelain,et al.  The pharmacology of second-generation chimeric antigen receptors , 2015, Nature Reviews Drug Discovery.

[91]  Yongping Song,et al.  Engineering switchable and programmable universal CARs for CAR T therapy , 2019, Journal of Hematology & Oncology.

[92]  J. Friedberg,et al.  Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[93]  A. Tutt,et al.  Repurposing Tin Mesoporphyrin as an Immune Checkpoint Inhibitor Shows Therapeutic Efficacy in Preclinical Models of Cancer , 2018, Clinical Cancer Research.

[94]  Daniel Li,et al.  Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. , 2017, Blood.

[95]  C. Doglioni,et al.  Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells , 2018, Nature Medicine.

[96]  Hao Liu,et al.  Clinical responses with T lymphocytes targeting malignancy-associated κ light chains. , 2016, The Journal of clinical investigation.

[97]  Ge Yang,et al.  Immunotherapy with CAR-Modified T Cells: Toxicities and Overcoming Strategies , 2018, Journal of immunology research.

[98]  J. Sprung,et al.  Anesthesia and Duchenne or Becker muscular dystrophy: review of 117 anesthetic exposures , 2013, Paediatric anaesthesia.

[99]  Seung Tae Lee,et al.  Rapid relapse of large B‐cell lymphoma after CD19 directed CAR‐T‐cell therapy due to CD‐19 antigen loss , 2019, American journal of hematology.

[100]  Colin R. F. Monks,et al.  Three-dimensional segregation of supramolecular activation clusters in T cells , 1998, Nature.

[101]  W. Wilson,et al.  Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. , 2010, Blood.

[102]  H. Heslop,et al.  T cell therapies. , 2006, Ernst Schering Foundation symposium proceedings.

[103]  S. Tu,et al.  Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment Strategies , 2019, Front. Immunol..

[104]  D. Scadden,et al.  Active movement of T cells away from a chemokine , 2000, Nature Medicine.

[105]  Sanjiv S. Gambhir,et al.  Trafficking Mesenchymal Stem Cell Engraftment and Differentiation in Tumor‐Bearing Mice by Bioluminescence Imaging , 2009, Stem cells.

[106]  B. Walker,et al.  Toward T Cell-Mediated Control or Elimination of HIV Reservoirs: Lessons From Cancer Immunology , 2019, Front. Immunol..

[107]  Jeffrey R. Whiteaker,et al.  Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function , 2018, Science Signaling.

[108]  T. Guo,et al.  Neurological toxicities and coagulation disorders in the cytokine release syndrome during CAR‐T therapy , 2018, British journal of haematology.

[109]  Hao Liu,et al.  Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[110]  C. June,et al.  A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors. , 2016, Cancer research.

[111]  Qing He,et al.  Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia , 2014, Science Translational Medicine.

[112]  Derek S. Chan,et al.  Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti–PD-L1 immunotherapy in pancreatic cancer , 2013, Proceedings of the National Academy of Sciences.

[113]  W. Lim,et al.  The Principles of Engineering Immune Cells to Treat Cancer , 2017, Cell.

[114]  Navdeep S. Chandel,et al.  Fundamentals of cancer metabolism , 2016, Science Advances.

[115]  R. Brentjens,et al.  CARs of the future , 2019, American journal of hematology.

[116]  Jingjing Cao,et al.  Versatile CAR T-cells for cancer immunotherapy , 2018, Contemporary oncology.

[117]  Michel Sadelain,et al.  Therapeutic T cell engineering , 2017, Nature.

[118]  Xiaojing Ma,et al.  CRISPR/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions , 2018, Cancer Immunology, Immunotherapy.

[119]  W. Han,et al.  Chimeric antigen receptor (CAR)-modified natural killer cell-based immunotherapy and immunological synapse formation in cancer and HIV , 2017, Protein & Cell.

[120]  K. Curran,et al.  Toxicity and management in CAR T-cell therapy , 2016, Molecular therapy oncolytics.

[121]  B. Levine,et al.  Engineered T cells: the promise and challenges of cancer immunotherapy , 2016, Nature Reviews Cancer.

[122]  Yang Feng,et al.  Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. , 2016, The Journal of clinical investigation.

[123]  Martin Pule,et al.  Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. , 2011, Blood.

[124]  Ruoning Wang,et al.  A Metabolism Toolbox for CAR T Therapy , 2019, Front. Oncol..

[125]  Omkar U. Kawalekar,et al.  CAR T cell immunotherapy for human cancer , 2018, Science.

[126]  C. Rooney,et al.  Enhanced Tumor Trafficking of GD2 Chimeric Antigen Receptor T Cells by Expression of the Chemokine Receptor CCR2b , 2010, Journal of immunotherapy.

[127]  Xiuli Wang,et al.  Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy. , 2016, The New England journal of medicine.

[128]  Bruce L Levine,et al.  PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR. , 2017, Blood.

[129]  Grant Bertolet,et al.  Super-resolution Imaging of the Natural Killer Cell Immunological Synapse on a Glass-supported Planar Lipid Bilayer , 2015, Journal of visualized experiments : JoVE.

[130]  Z. Eshhar,et al.  Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[131]  D. Teachey,et al.  Toxicity management for patients receiving novel T-cell engaging therapies , 2014, Current opinion in pediatrics.

[132]  F. Bushman,et al.  CD19-targeting CAR T cell immunotherapy outcomes correlate with genomic modification by vector integration. , 2019, The Journal of clinical investigation.

[133]  D. Teachey,et al.  Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies , 2014, Cancer journal.

[134]  H. Heslop,et al.  T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. , 2006, Blood.

[135]  Carlos A Ramos,et al.  CD19-CAR Trials , 2014, Cancer journal.

[136]  Kole T. Roybal,et al.  Paving New Roads for CARs. , 2019, Trends in cancer.

[137]  J. Tolar,et al.  Incorporation of Immune Checkpoint Blockade into Chimeric Antigen Receptor T Cells (CAR-Ts): Combination or Built-In CAR-T , 2018, International journal of molecular sciences.

[138]  J. Slaughter,et al.  Does Body Mass Index Predict Premature Cardiomyopathy Onset for Duchenne Muscular Dystrophy? , 2017, Journal of child neurology.

[139]  Hao Liu,et al.  CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[140]  Yang Feng,et al.  CD22-CAR T Cells Induce Remissions in CD19-CAR Naïve and Resistant B-ALL , 2017, Nature Medicine.

[141]  David L. Porter,et al.  Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia , 2015, Science Translational Medicine.

[142]  D. Gilham,et al.  CAR T-cell therapy: toxicity and the relevance of preclinical models. , 2015, Immunotherapy.

[143]  Hao Liu,et al.  Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma , 2008, Nature Medicine.

[144]  Hans Bitter,et al.  Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia , 2018, Nature Medicine.

[145]  P. Thall,et al.  Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. , 2020, The New England journal of medicine.

[146]  B. Savoldo,et al.  Chimeric antigen receptors (CARs) from bench-to-bedside. , 2013, Immunology letters.

[147]  S. Bromley,et al.  The immunological synapse: a molecular machine controlling T cell activation. , 1999, Science.

[148]  W. Wilson,et al.  B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. , 2012, Blood.

[149]  C. June,et al.  Emerging Cellular Therapies for Cancer. , 2019, Annual review of immunology.

[150]  M. Wurfel,et al.  Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells. , 2017, Cancer discovery.

[151]  C. Turtle,et al.  Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cells. , 2012, Blood.

[152]  A. Shimabukuro-Vornhagen,et al.  Understanding cytokine release syndrome , 2018, Intensive Care Medicine.

[153]  L. Álvarez-Vallina,et al.  Efficacy and toxicity management of CAR-T-cell immunotherapy: a matter of responsiveness control or tumour-specificity? , 2016, Biochemical Society transactions.

[154]  Qing He,et al.  CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia , 2013, Science Translational Medicine.